77894-69-0

Basic information

• Product Name: 1-Methyl-1H-indazol-4-ylamine
• Synonyms: 1-Methyl-1H-indazol-4-ylamine;1-Methyl-1H-indazole-4-amine;1-Methyl-1H-indazol-4-amine;1H-Indazol-4-aMine,1-Methyl-;4-AMino-1-Methylindazole;1-Methyl-4-aMino-1h-indazole;1-methylindazol-4-amine
• CAS NO: 77894-69-0
• Molecular Formula: C₈H₉N₃
• Molecular Weight: 147.18
• Product Categories: pharmacetical
• Mol File: 77894-69-0.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 321.6 °C at 760 mmHg
• Flash Point: 148.3 °C
• Appearance: /
• Density: 1.27 g/cm³
• Vapor Pressure: 0.000295mmHg at 25°C
• Refractive Index: 1.667
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 1-Methyl-1H-indazol-4-ylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Methyl-1H-indazol-4-ylamine(77894-69-0)
• EPA Substance Registry System: 1-Methyl-1H-indazol-4-ylamine(77894-69-0)

Safety Data

• Hazardous Substances Data: 77894-69-0(Hazardous Substances Data)

Usage

General Description

1-Methyl-1H-indazol-4-ylamine is a chemical compound with the molecular formula C8H9N3. It falls under the category of indazoles, which are organic compounds containing a benzene ring fused to a pyrazole ring. It is formed from the substitution of an unspecified indazole hydrogen by a methyl group. The amine group attached to the indazole ring lends basic properties to the compound. This chemical appears as a solid and is generally used as a building block in the synthesis of more complex organic compounds. It can be prepared in a laboratory setting using appropriate precursors. It may have various applications in biomedical research due to the important role indazole derivatives play in medicinal chemistry.

InChI:InChI=1/C8H9N3/c1-11-8-4-2-3-7(9)6(8)5-10-11/h2-5H,9H2,1H3

Upstream product

• 26120-43-4 1-methyl-4-nitro-1H-indazole 
• 64-17-5 ethanol 
• 2942-40-7 nitro-4 indazole 
• 365427-30-1 4-bromo-1-methyl-1H-indazole 
• 7440-44-0 pyrographite 
• 603-83-8 3-nitro-o-tolylamine 

Downstream Products

• 945396-55-4 N²-(3,5-dimorpholinophenyl)-N⁴-(1H-indazol-4-yl)-N⁴-methylpyrimidine-2,4-diamine 
• 1613391-40-4 C₂₀H₁₉N₃O₄ 
• 144528-23-4 1-methyl-1H-indazol-4-ol 
• 1378079-11-8 1-(5-Methanesulfonyl-2-methoxy-phenyl)-3-(1-methyl-1H-indazol-4-yl)-thiourea 
• 581810-87-9 N-[4-(1-azepanyl)-3-fluorobenzyl]-N'-(1-methyl-1H-indazol-4-yl)urea 
• 41748-71-4 4-aminoindazole 
• 581810-86-8 N-[4-(1-azepanyl)benzyl]-N'-(1-methyl-1H-indazol-4-yl)urea 

Relevant articles and documents

Development of indazolylpyrimidine derivatives as high-affine EphB4 receptor ligands and potential PET radiotracers

Due to their essential role in the pathogenesis of cancer, members of the Eph (erythropoietin-producing hepatoma cell line-A2) receptor tyrosine kinase family represent promising candidates for molecular imaging. Thus, the development and preparation of novel radiotracers for the noninvasive imaging of the EphB4 receptor via positron emission tomography (PET) is described. First in silico investigations with the indazolylpyrimidine lead compound which is known to be highly affine to EphB4 were executed to identify favorable labeling positions for an introduction of fluorine-18 to retain the affinity. Based on this, reference compounds as well as precursors were developed and labeled with carbon-11 and fluorine-18, respectively. For this purpose, a protecting group strategy essentially had to be generated to prevent unwanted methylation and to enable the introduction of fluorine-18. Further, a convenient radiolabeling strategy using [11C]methyl iodide was established which afforded the isotopically labeled radiotracer in 30-35% RCY (d.c.) which is identical with the original inhibitor molecule. A spiro ammonium precursor was prepared for radiolabeling with fluorine-18. Unfortunately, the labeling did not lead to the desired 18F-radiotracer under the chosen conditions.

TRPV1 ANTAGONISTS

Disclosed herein are compounds of Formula (I), or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS

The present invention relates to substituted benzofused derivatives, which can be used as vanilloid receptor ligands, method of treating diseases, conditions and/or disorders modulated by vanilloid receptors with them, and processes for preparing them.